The comment at the Cowen patent panel was that normally you would expect to see all these patents consolidated into one patent (and in fact they all incorporate terminal disclaimers, which supports that viewpoint). She speculated they did it this way mainly for PR purposes.
She said all the patents were based on the "surprise" that high-concentration EPA behaves differently from existing mixtures. She thought that if that "surpise" was valid the patents had a chance of standing up.
I personally haven't looked at any of the patents, but I would be very surprised if the cutoffs they mention for EPA concentration have any support at all - in other words if they claim 95% EPA purity, I would say that 94% would be clinically indistinguishable (remember there is some interconversion from EPA to DHA within the body).
Market Data 
Markets 
AI
